These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29541205)

  • 1. Monitoring colorectal cancer following surgery using plasma circulating tumor DNA.
    Sun X; Huang T; Cheng F; Huang K; Liu M; He W; Li M; Zhang X; Xu M; Chen S; Xia L
    Oncol Lett; 2018 Apr; 15(4):4365-4375. PubMed ID: 29541205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
    Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
    PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases.
    Polivka J; Windrichova J; Pesta M; Houfkova K; Rezackova H; Macanova T; Vycital O; Kucera R; Slouka D; Topolcan O
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing.
    Lee CS; Kim HS; Schageman J; Lee IK; Kim M; Kim Y
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Is Capable of Monitoring the Therapeutic Response and Resistance in Advanced Colorectal Cancer Patients Undergoing Combined Target and Chemotherapy.
    Cao H; Liu X; Chen Y; Yang P; Huang T; Song L; Xu R
    Front Oncol; 2020; 10():466. PubMed ID: 32318348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
    Wang JY; Hsieh JS; Chang MY; Huang TJ; Chen FM; Cheng TL; Alexandersen K; Huang YS; Tzou WS; Lin SR
    World J Surg; 2004 Jul; 28(7):721-6. PubMed ID: 15185002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
    He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
    Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer.
    Gong J; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hendifar A; Osipov A; Zaghiyan K; Cho M; Gangi A; Hitchins M
    Mol Clin Oncol; 2022 May; 16(5):100. PubMed ID: 35463213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
    Nguyen HT; Nguyen TV; Nguyen Hoang VA; Tran DH; Le Trinh NA; Le MT; Nguyen Tran TA; Pham TH; Dinh TC; Nguyen TS; Nguyen The KC; Mai H; Chu MT; Pham DH; Nguyen XC; Ngo Ha TM; Nguyen DS; Nguyen DQ; Lu YT; Do Thi TT; Truong DK; Nguyen QT; Nguyen HN; Giang H; Tu LN
    Front Oncol; 2022; 12():1069296. PubMed ID: 36578946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
    Hendricks A; Rosenstiel P; Hinz S; Burmeister G; Röcken C; Boersch K; Schafmayer C; Becker T; Franke A; Forster M
    BMC Med Genet; 2020 Jan; 21(1):3. PubMed ID: 31900123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
    Reinert T; Henriksen TV; Christensen E; Sharma S; Salari R; Sethi H; Knudsen M; Nordentoft I; Wu HT; Tin AS; Heilskov Rasmussen M; Vang S; Shchegrova S; Frydendahl Boll Johansen A; Srinivasan R; Assaf Z; Balcioglu M; Olson A; Dashner S; Hafez D; Navarro S; Goel S; Rabinowitz M; Billings P; Sigurjonsson S; Dyrskjøt L; Swenerton R; Aleshin A; Laurberg S; Husted Madsen A; Kannerup AS; Stribolt K; Palmelund Krag S; Iversen LH; Gotschalck Sunesen K; Lin CJ; Zimmermann BG; Lindbjerg Andersen C
    JAMA Oncol; 2019 Aug; 5(8):1124-1131. PubMed ID: 31070691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.
    Iwahashi N; Sakai K; Noguchi T; Yahata T; Toujima S; Nishio K; Ino K
    Oncol Lett; 2018 Nov; 16(5):6431-6436. PubMed ID: 30405780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The value of serum human tumor protein P53 in colorectal cancer combined diagnosis and postoperative monitoring].
    Fan P; Zhang Y; Deng F; Chen SH; Li M; Zhang Q
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2670-2673. PubMed ID: 28910954
    [No Abstract]   [Full Text] [Related]  

  • 20. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.